CD86 and neoplasm: In vivo, the development of a CD86‐P2A‐EGR3 recombinant mRNA vaccine not only triggers melanoma cells to undergo Schwann cell‐like differentiation but also augments immune infiltration via the NK‐cDCs‐CD8+T‐cell axis, ultimately resulting in effective tumor control.